水痘-带状疱疹病毒糖蛋白E在昆虫细胞中的表达、鉴定及免疫原性分析 <sup>*</sup>

doi:10.13523/j.cb.20190803

中国生物工程杂志

2019, Vol. 39

Issue (8): 17-24 DOI: 10.13523/j.cb.20190803

研究报告

水痘-带状疱疹病毒糖蛋白E在昆虫细胞中的表达、鉴定及免疫原性分析 ^*

齐家龙¹,高瑞雨¹,靳输梅²,高福兰¹,杨旭¹,马雁冰¹,刘存宝^1,^**(

)

1 中国医学科学院北京协和医学院医学生物学研究所昆明 65000
2 云南省药物研究所云南白药集团创新研发中心云南省中药和民族药新药创制企业重点实验室昆明 65000

Expression and Identification of Varicella-Zoster Virus Glycoprotein E and Immunogenicity Assay

QI Jia-long¹,GAO Rui-yu¹,JIN Shu-mei²,GAO Fu-lan¹,YANG Xu¹,MA Yan-bing¹,LIU Cun-bao^1,^**(

)

1 Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming 650000, China
2 Yunnan Institute of Materia Medica, Yunnan Baiyao Group Innovation and R&D Center, Yunnan Province Company Key Laboratory for TCM and Ethnic Drug of New Drug Creation, Kunming 650111, China;

全文: PDF(1891 KB) HTML

摘要：

目的: 利用昆虫-杆状表达系统建立表达和纯化分泌形式的水痘-带状疱疹病毒 (varicella-zoster virus, VZV) 糖蛋白gE的方法,并鉴定其理化性质及免疫原性。 方法: 利用Gibson assembly同源重组试剂盒快速构建重组质粒 pFastbac-VZV gE。在sf9昆虫细胞中鉴定序列优化前后表达量的差异,并在High Five ^TM细胞中大量表达。通过Ni-NTA亲和层析方法得到高纯度gE蛋白,之后通过酶联免疫吸附试验等验证了其理化性质,并进行小鼠免疫分析其免疫原性。 结果: 构建了pFastbac-VZV gE1/2重组质粒,经过PCR及双酶切鉴定后均为阳性克隆。使用BAC/PAC试剂盒提取Bacmid转染sf9细胞制备杆状病毒,经Western blot检测,sf9细胞开始表达gE蛋白且随着病毒代次升高gE蛋白表达量增加。序列优化后表达量明显增加,但是大部分以胞内形式存在。通过Ni-NTA一步亲和层析获得纯度较高的gE蛋白,并与VZV单抗9C8具有较好的反应性。通过免疫小鼠产生高滴度抗体,且免疫荧光结果显示其血清可以与天然病毒上的gE抗原结合。 结论: 成功获得了杆状表达系统表达的gE蛋白并且纯化和鉴定了蛋白质的性质及免疫原性,为进一步研发具有自主产权的VZV亚单位疫苗研究奠定了基础。

关键词： 水痘带状疱疹病毒; 糖蛋白gE; 昆虫表达系统; 免疫原性

Abstract:

Object: To establish an efficient Bac-to-Bac baculovirus expression system for the expression and purification of the secreted form of varicella-zoster virus (VZV) glycoprotein E (gE) and to evaluate the physical-chemical properties and immunogenicity of gE. Methods: Gibson assembly homologous recombination kit was used for pFastbac-VZV gE recombinant blasmid construction. Expression of the recombinant protein was prepared in baculovirus-infected High-Five ^TM insect cell after protein expression difference were identified between sequence optimization or non-optimization using sf9 insect cell. ELISA and Western blot were employed for the verification of physicochemical properties of Ni-NTA-exclusion chromatography purified protein gE. Immunogenicity assay of recombinant VZV gE was identified with serum titer determination and immunofluorescence reaction with na?ve VZV. Results: The pFastbac-VZV gE recombinant plasmid was successfully constructed according to PCR and enzyme digestion identification assay. Recombinant bacmids extracted with a BAC/PAC DNA extraction kit were transfected into sf9 insect cell for baculovirus preparation. VZV gE was expressed in baculovirus-infected sf9 cell in a generation-dependent increasing manner according to Western blot assay. Obviously, sequence optimization enhanced gE production, but most of the proteins existed intracellularly. Highly purified gE worked well with VZV monoclone antibody 9C8 by ELISA. High reaction titer of immune serum with gE was identified and immunofluorescence showed interaction between serum and VZV in APER-19 cell. Conclusion: VZV gE recombinant protein highly expressed in Bac-to-Bac baculovirus expression system are generated and laid the foundation for further research and development of VZV subunit vaccine.

Key words: Varicella-zoster virus Glycoprotein E Insect cell expression system Immunogenicity

收稿日期: 2019-01-04 出版日期: 2019-09-18

ZTFLH:

Q816

基金资助: *中国医学科学院医学与健康科技创新工程(2017-12M-3-022)

通讯作者: 刘存宝 E-mail: Cunbao_Liu@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	齐家龙
	高瑞雨
	靳输梅
	高福兰
	杨旭
	马雁冰
	刘存宝

引用本文:

齐家龙, 高瑞雨, 靳输梅, 高福兰, 杨旭, 马雁冰, 刘存宝. 水痘-带状疱疹病毒糖蛋白E在昆虫细胞中的表达、鉴定及免疫原性分析 ^*[J]. 中国生物工程杂志, 2019, 39(8): 17-24.

QI Jia-long, GAO Rui-yu, JIN Shu-mei, GAO Fu-lan, YANG Xu, MA Yan-bing, LIU Cun-bao. Expression and Identification of Varicella-Zoster Virus Glycoprotein E and Immunogenicity Assay. China Biotechnology, 2019, 39(8): 17-24.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20190803 或 https://manu60.magtech.com.cn/biotech/CN/Y2019/V39/I8/17

图1 重组质粒pFastbac-VZV gE1/2 构建及鉴定

图2 VZV糖蛋白gE的表达鉴定

图3 VZV 糖蛋白gE纯化和鉴定

图4 gE蛋白免疫原性分析

[1]	Arvin A M . Varicella-zoster virus:molecular virology and virus-host interactions. Curr Opin Microbiol, 2001,4(4):442-449. doi: 10.1016/S1369-5274(00)00233-2
[2]	Gilderman L I, Lawless J F, Nolen T M , et al. A double-blind, randomized,controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol, 2008,15(2):314-319.
[3]	Oxman M N, Levin M J, Johnson G R , et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 2005,352(22):2271-2284.
[4]	Cunningham A L, Lal H, Kovac M , et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med, 2016,375(11):1019-1032.
[5]	Davison A J, Scott J E . The complete DNA sequence of varicella-zoster virus. J Gen Virol, 1986,67(Pt 9):1759-1816.
[6]	Dendouga N, Fochesato M, Lockman L , et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine, 2012,30(20):3126-3135. doi: 10.1016/j.vaccine.2012.01.088
[7]	Sommer M H, Zagha E, Serrano O K , et al. Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69,of varicella-zoster virus. J Virol, 2001,75(17):8224-8239.
[8]	Garcia-Valcarcel M, Fowler W J, Harper D R , et al. Induction of neutralizing antibody and T-cell responses to varicella-zoster virus (VZV) using Ty-virus-like particles carrying fragments of glycoprotein E (gE). Vaccine, 1997,15(6-7):709-719.
[9]	Haumont M, Jacquet A, Massaer M , et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res, 1996,40(2):199-204.
[10]	Leroux-Roels I, Leroux-Roels G, Clement F , et al. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis, 2012,206(8):1280-1290. doi: 10.1093/infdis/jis497
[11]	Berkowitz E M, Moyle G, Stellbrink H J , et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults:a phase 1/2a randomized,placebo-controlled study. J Infect Dis, 2015,211(8):1279-1287.
[12]	Wang W, Pan D, Fu W , et al. A SCID mouse-human lung xenograft model of varicella-zoster virus infection. Antiviral Res, 2017,146:45-53. DOI: 10.1016/j.antiviral.2017.08.012. doi: 10.1016/j.antiviral.2017.08.012
[13]	Wang W, Yang L, Huang X , et al. Outer nuclear membrane fusion of adjacent nuclei in varicella-zoster virus-induced syncytia. Virology, 2017,512:34-38. DOI: 10.1016/j.virol.2017.09.002. doi: 10.1016/j.virol.2017.09.002
[14]	Wang W, Fu W, Pan D , et al. Varicella-zoster virus ORF7 interacts with ORF53 and plays a role in its trans-Golgi network localization. Virologica Scinica, 2017,32(5):387-395.
[15]	Selariu A, Cheng T, Tang Q , et al. ORF7 of varicella-zoster virus is a neurotropic factor. J Virol, 2012,86(16):8614-8624. doi: 10.1128/JVI.00128-12
[16]	Zhang Z, Selariu A, Warden C , et al. Genome-wide mutagenesis reveals that ORF7 is a novel VZV skin-tropic factor. PLoS Pathog, 2010,6(7):e1000971.
[17]	Jiang H F, Wang W, Jiang X , et al. ORF7 of varicella-zoster virus is required for viral cytoplasmic envelopment in differentiated neuronal cells. J Virol, 2017,91(12):e00127-17.
[18]	Zhu R, Liu J, Chen C , et al. A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. Vaccine, 2016,34(13):1589-1596.
[19]	Wu Y, Zhu R, Xu L , et al. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine, 2017,35(20):2728-2735.
[20]	Liu J, Zhu R, Ye X , et al. A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine. Appl Microbiol Biotechnol, 2015,99(11):4845-4853.
[21]	Liu C, Yao Y, Yang X , et al. Production of recombinant human papillomavirus type 52 l1 protein in hansenula polymorpha formed virus-like particles. J Microbiol Biotechnol, 2015,25(6):936-940.
[22]	Zhang J, Zhang X F, Huang S J , et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med, 2015,372(10):914-922.
[23]	Liu J, Chen C, Zhu R , et al. Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay. Appl Microbiol Biotechnol, 2016,100(21):9321-9329.
[24]	Gibson D G, Young L, Chuang R Y , et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods, 2009,6(5):343-345.
[25]	Reed S G, Orr M T, Fox C B . Key roles of adjuvants in modern vaccines. Nat Med, 2013,19(12):1597-1608.

[1]	岑黔鸿,高彤,任怡,雷涵. 重组酿酒酵母表达幽门螺杆菌VacA蛋白及其免疫原性分析^*[J]. 中国生物工程杂志, 2020, 40(5): 15-21.
[2]	杜力,刘晓志,高健,王志明. 抗体药物免疫原性评估的研究进展[J]. 中国生物工程杂志, 2018, 38(2): 89-94.
[3]	吴剑荣,彭星桥,詹晓北. 聚唾液酸,一种非GAGs、非免疫原性生物材料的应用研究进展 ^*[J]. 中国生物工程杂志, 2017, 37(12): 96-102.
[4]	王晶, 夏文跃, 潘小霞, 赵冰心, 滕玉梅, 李传印, 杨筱舟, 文喻玲, 陈元鼎. 研究报告Ⅱ型脊灰病毒抗原表位嵌合蛋白的免疫学研究[J]. 中国生物工程杂志, 2016, 36(8): 1-8.
[5]	夏文跃, 王晶, 赵冰心, 潘小霞, 文喻玲, 陈元鼎. 轮状病毒VP4抗原表位在VP6载体蛋白同一位点表达比较研究[J]. 中国生物工程杂志, 2015, 35(8): 9-15.
[6]	李多, 杨丽娟, 赵玉娇, 潘玥, 陈俊英, 付娟娟, 黄新伟, 邱丽娟, 孙强明. 研究报告重组Ⅱ型登革病毒NS1的表达及其免疫原性的研究[J]. 中国生物工程杂志, 2014, 34(9): 4-8.
[7]	孙颖, 张灵霞, 吴雪琼, 董恩军. mpt64-卡介苗重组疫苗的构建、免疫原性及抗结核作用[J]. 中国生物工程杂志, 2011, 31(7): 14-19.
[8]	魏林, 邱飞, 刁勇. 腺病毒载体的高分子修饰[J]. 中国生物工程杂志, 2011, 31(06): 111-115.
[9]	王正茂李琳管文燕李越希. 真核细胞表达单纯疱疹病毒I型包膜糖蛋白B及其抗原性与免疫原性分析[J]. 中国生物工程杂志, 2010, 30(06): 8-13.
[10]	陈柳李健峰徐维明戴宗祥李智华孙强明. 脑膜炎奈瑟氏菌外膜蛋白NhhA的克隆表达及免疫学分析[J]. 中国生物工程杂志, 2010, 30(04): 8-12.
[11]	阳泰,王红宁,汪雪,高荣,唐俊妮,李玉玲,郭自城. 抗禽传染性支气管炎病毒多肽疫苗EpiA免疫原性研究[J]. 中国生物工程杂志, 2009, 29(03): 20-24.
[12]	徐海,侯红岩,邓碧华,郑其升,侯继波. 禽流感病毒M2、NP融合蛋白与多种佐剂的联合运用及对免疫原性影响[J]. 中国生物工程杂志, 2009, 29(02): 42-47.
[13]	简中友,贾贇,王全凯,胡传伟,肇慧君,李叶. 狐源犬瘟热病毒CDV-FOX-TA株核蛋白基因的原核表达及鉴定[J]. 中国生物工程杂志, 2008, 28(7): 53-57.
[14]	计越,金宁一,鲁会军,马鸣潇,金明兰,霍晓伟,郑敏,李旭,刘慧娟. 载基因壳聚糖纳米粒的制备及免疫增强作用的初步研究[J]. 中国生物工程杂志, 2008, 28(2): 37-41.
[15]	高燕,孙明,蒋国润,张银川,王玺,李冰香,陈丹,黄小琴,周东霞,褚嘉祐. HIV-1 C/B'亚型多价重组MVA病毒疫苗[J]. 中国生物工程杂志, 2008, 28(2): 10-15.

Viewed

Full text

Abstract

Cited

Shared

Discussed